百家乐怎么玩-澳门百家乐官网娱乐城网址_网上百家乐是不是真的_全讯网888 (中国)·官方网站

Submitted by cheukllui3 on
Anti-Cancer
Chemical Biology
Chemistry
Novel tridimensional anticancer agents developed to fight against drug-resistant cancer cells

A research team co-led by chemists from City University of Hong Kong (CityU) recently discovered novel, highly effective anticancer agents with tridimensional structures, which have high anticancer activity, low toxicity and the ability to overcome drug resistance in cancer cells. The findings help provide a new direction for anticancer drug development.

Cancer has long been a devastating disease, which affects millions of people worldwide. Despite advances in treatment, current anticancer drugs often have limited effectiveness, lack of cancer selectivity, serious side effects and drug resistance in cancer cells.

“The structure of drugs greatly affects their anticancer performance,” explained Dr. Guangyu Zhu in the Department of Chemistry at CityU. “Most anticancer drugs have planar structures; developing new compounds with tridimensional structures may provide an opportunity to address the limitations of current anticancer drugs.”

In collaboration with researchers from The Hong Kong University of Science and Technology (HKUST), the team tested a new class of tridimensional and chiral compounds, which exhibit promising anticancer activity and present action mechanisms that are distinct from conventional anticancer drugs to overcome drug resistance.

anticancer agents
The half maximal inhibitory concentration (IC50 value) of synthetic lead compounds and clinical drug doxorubicin (DOX) in lung cancer stem cells and normal cells after incubation for 72 hours. Credit: Dr. Guangyu Zhu’s Research Group / City University of Hong Kong

The team first developed a new, highly efficient catalytic synthetic strategy to obtain a novel class of tridimensional and chiral tetraarylmethane compounds that presented better anticancer activity and lower toxicity than the clinical anticancer drug doxorubicin.

In their experiments, the research team tested the compounds with cancer cells in vitro, using doxorubicin as a control. They found that the tetraarylmethane compounds were more cytotoxic to cancer cells, including lung cancer stem cells (LCSCs), which are notorious for their drug resistance to clinical chemotherapeutic drugs, causing treatment failure. The compound also exhibited better cancer cell selectivity as it caused less harm to normal living cells, suggesting lower toxicity.

anticancer agents
SAR analysis of the synthetic compounds. The key factors that
contribute to the anticancer activity of this type of compound are indicated. The presence of certain substituents, including halogen and hydroxyl groups, at certain positions in the tetraarylmethane compounds significantly improves cytotoxicity. TMS, trimethylsilyl; Me, methyl. Credit: ? Tan, X. et al.: https://www.nature.com/articles/s44160-022-00211-4

The team further analyzed the structure-activity relationship of synthesized compounds. They found that the presence of certain substituents, including halogen and hydroxyl groups, at certain positions of the tetraarylmethane compounds significantly improved their cytotoxicity to cancer cells. Upon treatment with the synthesized compound, some cancer cells started to die, as organelle swelling, cell membrane permeabilization, nuclear shrinkage and fragmentation were observed. This suggests that necrotic cell death might have been triggered by the tetraarylmethane compounds.

In the fight against cancer, the majority of anticancer drugs currently available rely on the activation of apoptotic pathways to eliminate cancer cells. However, a promising new avenue of research for reducing drug resistance lies in the development of novel anticancer agents that target alternative cell death pathways. In their experiments, the team found that these innovative compounds induced a different cell death pathway. This suggests that the compounds can bypass the resistance mechanisms generated by conventional drugs, making them highly desirable for further exploration in the field of cancer treatment.

“The satisfactory anticancer performance and unique mechanism make these compounds potential candidates for anticancer agents for further development,” said Dr. Zhu. The team plans to synthesize more compounds and conduct further experiments to evaluate their anticancer performance.

anticancer agents
The synthesised lead compounds induced necroptosis in lung cancer stem cells. The arrows indicate cell membrane permeabilization. Credit: ? Tan, X. et al. https://www.nature.com/articles/s44160-022-00211-4

Their findings were published in the scientific journal Nature Synthesis under the title "Enantioselective synthesis of tetraarylmethanes through meta-hydroxyl-directed benzylic substitution".

The corresponding authors are Dr. Zhu and Professor Jianwei Sun from HKUST. The co-first authors are Dr. Xuefeng Tan from HKUST and Dr. Zhiqin Deng, former postdoc in Dr Zhu’s research group at CityU.

The research received financial support from the National Natural Science Foundation of China, the Science, Technology and Innovation Committee of Shenzhen Municipality, the Hong Kong Research Grants Council, and the Innovation and Technology Commission.

 

This research article originated from CityU Research Stories.

永利百家乐官网赌场娱乐网规则| 网上百家乐赌法| 百家乐官网改单软件| 苏尼特右旗| 大发888 娱乐| 电子百家乐打法| 百家乐棋牌游戏源码| 百家乐群东方鸿运| 百家乐官网赢钱公式论| 赌博百家乐官网游戏| 赙彩百家乐官网游戏规则| 禄劝| 都江堰市| 大发888官方6222.c| 百家乐大轮转| 百家乐推锅| 网上百家乐是假| 百家乐大娱乐场开户注册| 赌百家乐容易的原| 乐天堂百家乐娱乐平台| 威尼斯人娱乐城老品牌值得您信赖lm0 | 火箭百家乐的玩法技巧和规则| 百家乐赌博合作| 百家乐免费送现金| 百家乐多少钱| 博彩百家乐字谜总汇| 百家乐官网平的概率| 百家乐官网tt娱乐场开户注册 | 大发888总结经验| 百家乐博彩策略论坛| 大连百家乐官网食品| 百家乐官网赢钱公式论| 可信百家乐官网的玩法技巧和规则 | 百家乐平点| 二八杠高手| 沙龙国际娱乐网| 墨江| 百家乐官网2万| 百家乐官网单人操作扫描道具 | 888百家乐的玩法技巧和规则 | 娱乐|